Research Paper Volume 13, Issue 9 pp 13006—13022

A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody

PET imaging studies of 68Ga-NOTA-Nb109. (A) Dynamic PET scanning of MC38 tumor–bearing models (with or without injection of Sindilizumab) over 0–2 h after injection of 4.0–5.0 MBq of 68Ga-NOTA-Nb109. (n=3, tumors indicated by the yellow arrow). (B) Tumor-to-muscle (T/M) ratio of 68Ga-NOTA-Nb109 was analyzed according to the quantification analysis of PET images.

Figure 3. PET imaging studies of 68Ga-NOTA-Nb109. (A) Dynamic PET scanning of MC38 tumor–bearing models (with or without injection of Sindilizumab) over 0–2 h after injection of 4.0–5.0 MBq of 68Ga-NOTA-Nb109. (n=3, tumors indicated by the yellow arrow). (B) Tumor-to-muscle (T/M) ratio of 68Ga-NOTA-Nb109 was analyzed according to the quantification analysis of PET images.